Drug profile · INN
tafamidis meglumine
VYNDAQEL INITIAL APPROVAL
tafamidis meglumine (VYNDAQEL INITIAL APPROVAL) is a transthyretin stabiliser. Route of administration: oral. Current US regulatory status: approved.
Drug details — tafamidis meglumine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 1
- Data quality
- 0.84
Quick answer
tafamidis meglumine (VYNDAQEL INITIAL APPROVAL) is a transthyretin stabiliser. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Transthyretin stabiliser
Primary target: Transthyretin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12391663
Isoindolinone compounds
granted -
US 12378199
Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules
granted -
US 12263143
Ionic channel modulation as a method for treating tumors through inflammasome activation
granted -
US 12070628
Low energy immune priming for treating cancer and metastasis
granted -
US 12011619
Low intensity focused ultrasound for treating cancer and metastasis
granted -
US 11912682
Isoindolinone compounds
granted -
US 11344631
Promoter for cell-specific gene expression and uses thereof
granted -
US 11279922
Delivery of therapeutic agents by a collagen binding protein
granted -
US 11246858
Immunoresponsive methods of treating tumors
granted -
US 11001820
Delivery of therapeutic agents by a collagen binding protein
granted -
US 10974077
Low intensity focused ultrasound for treating cancer and metastasis
granted -
US 10772846
Methods and compositions for treating and preventing arthritis
granted -
US 10519138
Modulators of SOCE, compositions, and uses thereof
granted -
US 10213488
Delivery of therapeutic agents by a collagen binding protein
granted -
US 10104882
Methods and compositions for preventing and treating electrophile-mediated toxicities
granted -
US 9579273
Delivery of therapeutic agents by a collagen binding protein
granted -
US 9556438
Gene vector
granted -
US 9526765
Delivery of therapeutic agents by a collagen binding protein
granted -
US 8835510
Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins
granted -
US 8574653
Intermittent flow extrusion process and food product
granted
Frequently asked questions
What is tafamidis meglumine?
tafamidis meglumine (VYNDAQEL INITIAL APPROVAL) is a transthyretin stabiliser. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tafamidis meglumine?
VYNDAQEL INITIAL APPROVAL is a marketed brand name for tafamidis meglumine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tafamidis meglumine?
tafamidis meglumine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.